Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) reported conclusive results from its bioavailability trial comparing its sublingual aspirin to standard chewed aspirin tablets. The trial, involving healthy adults, assessed safety, tolerability, pharmacokinetics, and pharmacodynamics.
The sublingual aspirin demonstrated superior and faster absorption of acetylsalicylic acid (ASA) into the bloodstream compared to the chewed tablets. Importantly, this translated to a more rapid reduction in serum thromboxane B2 (TxB2), a key biomarker indicating aspirin’s effectiveness in preventing blood clot formation.
This rapid TxB2 inhibition, observed within two minutes of administering Aspire‘s sublingual formulation, is critically important in treating suspected heart attacks. The speed of action is approximately double that of currently recommended chewed aspirin.
The study highlights the potential of Aspire‘s sublingual aspirin to become a leading treatment for acute myocardial infarction (AMI), commonly known as a heart attack. Considering the high incidence of coronary artery disease and AMI in the United States, this rapid-acting formulation could significantly improve patient outcomes.
Kraig Higginson, Aspire‘s Interim Chief Executive Officer, expressed confidence in the product’s life-saving potential. He emphasized the significantly faster TxB2 inhibition observed in the trial and the company’s intention to submit the data to the U.S. Food and Drug Administration (FDA) for accelerated approval. Aspire aims to submit this application in the third quarter of 2025.
The trial used a 162.5 mg dose of aspirin, aligning with current guidelines for initial treatment of suspected AMI. The results suggest a considerable advantage over the current standard of care, which involves chewing uncoated aspirin tablets. Faster platelet inhibition, as demonstrated by the reduced TxB2 levels, could be crucial in minimizing heart muscle damage during a heart attack.
Aspire‘s sublingual aspirin employs a patent-pending technology that delivers medication directly into the bloodstream, bypassing the gastrointestinal tract. This technology could lead to improved drug efficacy and reduced side effects. The company plans to leverage this technology for other drugs and bioactive substances in the future.
The clinical trial, AB-101, used a randomized crossover design, comparing Aspire‘s two sublingual formulations to a commercially available chewed aspirin tablet (Bayer). The study’s primary objective was to evaluate ASA bioavailability, with a secondary objective of assessing the effect on TxB2.
Aspire Biopharma‘s sublingual aspirin is currently an investigational new drug and has not yet received marketing approval from the FDA or other regulatory bodies. However, the positive trial results represent a significant step toward potential commercialization. The company is actively working to secure regulatory approval to bring this potentially life-saving medication to patients.
Related
